Continuing Education Activity

Pentoxifylline is a xanthine derivative used in the management of peripheral vascular disease. As a phosphodiesterase inhibitor (PDEi), the drug improves blood flow by reducing viscosity and enhancing red blood cell flexibility. This activity outlines the mechanism of action, administration, indications, off-label uses, adverse drug reactions, and contraindications. Additionally, this activity reviews the pharmacokinetics, monitoring strategies, and clinical toxicology of pentoxifylline. Given the complexity of its pharmacological actions and potential interactions with other medications, clinicians must be well-versed in prescribing pentoxifylline appropriately and monitoring patients for adverse effects.

Clinicians should weigh the risks and benefits before prescribing pentoxifylline, with pharmacists playing a pivotal role in dose optimization to minimize adverse reactions. Empowering prescribing clinicians is essential for optimizing patient care and preventing adverse outcomes in associated cardiovascular conditions. Through interprofessional collaboration, teams can leverage collective expertise to optimize pentoxifylline therapy outcomes, improving patient well-being and healthcare delivery as a result.

Objectives:

• Identify appropriate indications for pentoxifylline in the management of peripheral vascular disease.
• Differentiate between common adverse reactions associated with pentoxifylline and other medications used for similar conditions.
• Assess patient response to pentoxifylline therapy and adjust the regimen as necessary for optimal outcomes.
• Implement effective collaboration among interprofessional team members to improve treatment efficacy for patients who might benefit from pentoxifylline.

Indications

Pentoxifylline is a vasoactive agent that improves blood flow by reducing viscosity.

FDA-Approved Indications

Pentoxifylline is FDA-approved for the symptomatic treatment of claudication. The drug is inferior to cilostazol or a supervised exercise program. Claudication is associated with chronic occlusive peripheral vascular disorders of the lower extremities.[1][2] The drug may improve tissue perfusion in such patients by enhancing blood flow and alleviating ischemic pain signs and symptoms.[3] Although this medication can alleviate symptoms, it is not meant to substitute standard treatments for peripheral vascular disease. Moreover, the American College of Chest Physicians and American Heart Association/American College of Cardiology (AHA/ACC) guidelines do not endorse pentoxifylline as a definitive treatment of peripheral arterial disease.[4] However, a network meta-analysis concluded that pentoxifylline is effective for the symptomatic treatment of intermittent claudication.[5][6]

Off-Label Uses

• Venous ulcers: A Cochrane review found pentoxifylline effective in treating venous ulcers with or without compression therapy compared to placebo or no treatment.[7] 

• Severe alcoholic hepatitis: Pentoxifylline is a tumor necrosis factor-α (TNF-α) inhibitor, a major cytokine in the pathogenesis of alcoholic hepatitis. In a meta-analysis, researchers noted pentoxifylline was superior to placebo in preventing fatal hepatorenal syndrome without any survival benefit in 1 month. Pentoxifylline is a suitable treatment for severe alcoholic hepatitis when contraindications to corticosteroids exist.[8]

• Osteoradionecrosis: Liquid pentoxifylline and vitamin E are promising as alternative formulations for patients with dysphagia or enteric feeding, offering clinical benefits for established osteoradionecrosis and prophylaxis before dental procedures. Retrospective data reveal favorable outcomes, with a high proportion of surgical sites healing completely and minimal reported adverse effects. More research is needed as the metanalysis findings provided insufficient evidence.[9][10][11]

Mechanism of Action

Pentoxifylline and the metabolites decrease blood viscosity and improve blood flow and peripheral tissue oxygenation. The precise mechanism of action that leads to symptom improvement remains yet to be determined. However, several pathways are likely involved.

• Pentoxifylline increases red blood cell flexibility by increasing erythrocyte ATP and cyclic nucleotide levels. This reduces blood viscosity by decreasing erythrocyte aggregation and stimulating fibrinolysis to reduce plasma fibrinogen concentrations. All these effects enhance the ability of blood to flow through peripheral vessels (hemorheological action).

• Pentoxifylline is a PDEi. By blocking the membrane-bound phosphodiesterase, pentoxifylline increases the concentration of cyclic AMP. The drug also inhibits thromboxane synthesis and increases prostacyclin synthesis. These actions result in reduced platelet aggregation. Further, pentoxifylline has demonstrated decreased adhesion of platelets to the vessel wall in patients with circulatory disorders.[12]

• Pentoxifylline exerts vasodilation in the skeletal muscle vascular bed by inhibiting PDE and increasing the cAMP.[13]

• Pentoxifylline inhibits the leukocyte-derived free radicals generated during peripheral ischemia in patients with peripheral vascular disease. This has been shown to reduce the impairment of the filterability rate of unfractionated leucocytes, limiting ischemia-related tissue damage.[14]

• Pentoxifylline has immunomodulatory effects. The drug improves leukocyte deformability and chemotaxis, leading to depressed neutrophil degranulation, decreased endothelial leukocyte adhesion, and lowered sensitivity of leukocytes to cytokines. Pentoxifylline can inhibit the production of inflammatory cytokines.[15] 

Several animal studies have demonstrated the role of pentoxifylline in attenuating ischemia-reperfusion injury, drug-induced nephrotoxicity, infection, and inflammation.

• Pentoxifylline minimized the ischemia-related tissue damage to the intestinal mucosa during reperfusion in Wistar rats.[16] 

• Treatment with pentoxifylline attenuated methotrexate-induced renal tissue injury cell death and suppressed the elevation of blood urea nitrogen and creatinine levels in Wistar rats.[17]

• Pentoxifylline exerts a beneficial, gastroprotective effect against stress-induced gastric lesions by improving gastric microcirculation in Wistar rats. This effect is likely due to the enhanced nitric oxide synthase (NOS) activity, local action of the nitric oxide, and attenuation of oxidative metabolism and proinflammatory cytokines.[18]

• In a murine macrophage cell line model, pentoxifylline reduced TNF protein levels by inhibiting TNF mRNA transcription in response to bacterial infection.[19]

• Pentoxifylline minimized liver damage induced by ischemia-reperfusion in albino rats.[20]

Multiple clinical studies have demonstrated the role of pentoxifylline's anti-inflammatory, anti-fibrotic, and hemorheological properties in various disease states.

• In a prospective randomized study, pentoxifylline demonstrated a statistically significant reduction in hemolysis during cardiopulmonary bypass compared to the control sample of patients.[21]

• In a prospective, placebo-controlled, randomized clinical trial of coronary artery bypass graft candidates with an ejection fraction lower or equal to 30%, pretreatment with pentoxifylline for 3 days before the procedure was associated with reduced tumor necrosis factor-α level, interleukin-6 level, improved left ventricular ejection fraction, decreased intensive care unit stay, ventilation time, and need for inotropic agents and blood transfusion.[22]

• In patients with type-2 diabetic nephropathy on ACEi or angiotensin receptor blockers (ARBs) for more than 6 months and on conventional treatment, the addition of pentoxifylline therapy reduced proteinuria and improved glucose control and insulin resistance without a significant change of serum TNF-α in patients.[23]

• Oral administration of pentoxifylline can improve cerebral blood flow in patients with cerebrovascular disease.[24]

• In a double-blind placebo-controlled trial, administering pentoxifylline to patients with multi-infarct dementia showed intellectual and cognitive function improvements.[25]

Pharmacokinetics

Absorption: Pentoxifylline is rapidly and completely absorbed in the gastrointestinal (GI) tract after oral administration. The drug is usually recommended with meals (food or milk) to minimize GI irritation. It is usually a sustained-release tablet with an early peak plasma pentoxifylline concentration 2 to 3 hours postadministration.

Bioavailability: 20% to 30%, because of a high first-pass clearance.[26][27]

Metabolism: Erythrocytes and the liver extensively metabolize pentoxifylline to its active metabolites (M1).[28]

Excretion: Pentoxifylline and its metabolites are primarily eliminated by the kidneys and less than 5% by feces. On the other hand, its key metabolites are also secreted in breast milk. The half-life of pentoxifylline is about 0.4 to 0.8 hours, and the metabolites are about 1 to 1.5 hours.

Administration

Available Dosage Forms and Strengths

Generic name: Pentoxifylline

Chemical name: 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione.

Solubility: Pentoxifylline is soluble in chloroform, methanol, and water.

Dosage form: Pentoxifylline is available as a 400 mg extended-release oral tablet.

Adult Dosing

Intermittent claudication: 400 mg orally 3 times per day with meals. Reduce the dose to 400 mg twice daily if GI intolerance is observed.[2][28]

Off-Label Indications

• Severe alcoholic hepatitis: 400 mg orally 3 times daily for 4 weeks.[29]

• Venous leg ulcer: 400 mg orally 3 times daily.[30][7]

• Treatment of neuropathic pain secondary to diabetic neuropathy: 400 mg orally 3 times daily after meal.[31]

• Treatment of Kawasaki disease: The recommended dosage is 20 mg/kg/day to reduce the prevalence of coronary artery lesions.[32][33]

• Pentoxifylline has been used in isolated case reports for specific indications. In Behcet syndrome-related ocular disease, a 2-week regimen of 600 mg per oral has been used. For prophylaxis against acute claudication in sickle cell disease, a dosage of 400 mg per oral 3 times daily after meals has been suggested. Further research is needed to validate its efficacy and safety in these contexts.[34][35]

Specific Patient Population

Hepatic impairment: Pentoxifylline should be used with caution in mild to moderate liver impairment as it may cause an increase in the exposure of pentoxifylline and its active metabolite. The use of pentoxifylline should be avoided in severe hepatic impairment.

Renal impairment: In patients with renal impairment and creatinine clearance (CrCl) below 30 mL/min, the dose of pentoxifylline should be reduced to 400 mg/day.

Pregnancy considerations: Pentoxifylline crosses the placenta in mice; evidence in humans is lacking. Therefore, it is not recommended for pregnant women unless the benefits outweigh the risks.

Breastfeeding considerations: Caution is advised when administering pentoxifylline to breastfeeding mothers, as pentoxifylline and its metabolites can be secreted in milk. Although evidence indicates that the drug is generally safe for breastfed infants, particularly those older than 2 months, it is advised to carefully consider whether to continue nursing or cease the medication, weighing the drug's significance for the mother.[36]

Pediatric patients: Pentoxifylline in patients aged below 18 is not advised because its safety profile and efficacy have not yet been established.

Older patients: The older patients exhibit higher peak plasma levels of the metabolites of pentoxifylline, leading to potential toxicity. Starting the pentoxifylline dosage at a lower level is recommended, considering polypharmacy and impaired renal/hepatic/cardiac function.

Adverse Effects

The most common adverse effect of pentoxifylline is nausea and vomiting. Other common adverse drug reactions are listed below.

• GI system: Abdominal discomfort, bloating, and diarrhea

• Cardiovascular system: Flushing; other infrequent side-effects are chest pain, arrhythmias, hypertension, dyspnea, tachycardia, and hypotension.

• Central nervous system: Dizziness, headache[5]

Drug-Drug Interactions

• Antihypertensive agents: Pentoxifylline has been used with antihypertensive drugs, including beta blockers and diuretics. Some patients treated with pentoxifylline and nifedipine or captopril have shown slight reductions in blood pressure.[37][38] Periodic monitoring of systemic blood pressure in patients receiving concurrent antihypertensive therapy with pentoxifylline is recommended. If necessary, consider adjusting the dosage of the antihypertensive agents.

• Oral hypoglycemic drugs: In animal studies, pentoxifylline enhances the anti-glycemic action of antidiabetic agents such as glibenclamide or metformin. Pentoxifylline has been demonstrated to inhibit ATP-sensitive K channels similar to glyburide in diabetic rats.[39] A dose reduction of anti-glycemic agents and glucose monitoring is recommended.

• Antiplatelet drugs: Pentoxifylline can increase the risk of bleeding in patients taking warfarin or antiplatelet agents. Monitoring PT/INR is recommended. The study has demonstrated that in patients with chronic kidney disease, the administration of pentoxifylline, particularly at daily doses exceeding 800 mg, requires monitoring for bleeding risk, especially in patients with a history of ischaemic stroke and regular aspirin use.[40]

• Theophylline: Pentoxifylline increases the plasma levels of theophylline by decreasing the clearance of theophylline, necessitating therapeutic drug monitoring.[41]

• Ketolorac: Administering ketorolac concurrently with pentoxifylline should be avoided due to increased bleeding risk.[42]

Contraindications

The following are contraindications to pentoxifylline:

• Patients with recent retinal or cerebral hemorrhage
• Allergy to xanthine derivatives, eg, caffeine, theophylline, theobromine[43]

Precautions

• Acute myocardial infarction or severe coronary disease due to increased risk of myocardial demand
• Severe liver disease (Child-Pugh class C) or cirrhosis
• Anaphylaxis due to pentoxifylline has been reported. Do not administer pentoxifylline in patients with a history of anaphylaxis.[44]
• Patients receiving pentoxifylline, particularly those with a history of peptic ulceration, recent surgery, or at risk of bleeding, especially in individuals with chronic kidney disease, should undergo regular assessments for signs of bleeding, including monitoring hematocrit and hemoglobin levels.[40]

Monitoring

Older patients are at higher risk of adverse effects from pentoxifylline. Careful monitoring of blood pressure and glucose levels is recommended when administering pentoxifylline to patients on antihypertensive and antidiabetic medications. They are at high risk for hypotension, falls, and hypoglycemia. Patients with liver disease should also undergo follow-up with periodic laboratory monitoring. Patients at increased risk of bleeding should be advised of potential signs and symptoms of bleeding and monitored with periodic laboratory data, including hematocrit and hemoglobin. Clinicians should exercise caution with cardiac arrhythmias and low blood pressure patients. Ankle-brachial index (ABI), pain-free walking distance, and maximum walking distance should be monitored for patients with peripheral arterial disease.[5][45]

Toxicity

Signs and Symptoms of Overdose 

Reports of adverse effects of pentoxifylline are apparent in patients on chronic hemodialysis.[46] Metabolic acidosis, hypokalemia, and arrhythmias are the primary symptoms of pentoxifylline overdose. Additionally, oliguria, cardiovascular collapse, and altered consciousness, including delirium, agitation, and coma, have been reported.

Management of Overdose

No reported antidote is available for this medication. The prescriber should discontinue the drug in suspected cases of toxicity. The symptomatic treatment includes administering IV fluids, NaHCO₃ supplementation, and norepinephrine infusion. In cases of significant overdose, consideration should be given to gastric lavage. Extracorporeal elimination is not currently recommended; however, it may be a viable option for patients with severe metabolic acidosis or impaired kidney function.[47][48]

Enhancing Healthcare Team Outcomes

Clinicians should prescribe pentoxifylline after considering the risk-benefit analysis. Pharmacists play a crucial role in determining the proper dose of medication to minimize adverse drug reactions. A retrospective cohort study analyzed the association between a specialist clinical pharmacist collaborating with medical staff and prescribing practices in peripheral arterial disease. The study compared 2 patient groups admitted to a vascular surgery unit in 2007 (control group) before the introduction of a comprehensive clinical pharmacy service and in 2009 (comparison group) after its implementation. Data was collected from electronic reports and medical records, revealing significant improvements in medication initiation and risk factor management with the inclusion of a clinical pharmacist in the collaborative healthcare team.[49] 

The contributions of both nurses and dieticians are essential to educating patients, ensuring medication adherence, and making necessary adjustments to mitigate risk factors associated with atherosclerotic disease. Complex cases of peripheral vascular disease should be managed in consultation with vascular surgeons. In overdose, emergency medicine clinicians should rapidly stabilize patients. Significant overdose may require MICU admission under the supervision of critical care. If the overdose is intentional, close consultation with a psychiatrist is needed. An interprofessional team approach between clinicians (MDs, DOs, NPs, PAs), pharmacists, nurses, and specialists is required to optimize patient outcomes related to pentoxifylline pharmacotherapy.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Girolami B, Bernardi E, Prins MH, Ten Cate JW, Hettiarachchi R, Prandoni P, Girolami A, Büller HR. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med. 1999 Feb 22;159(4):337-45. [PubMed: 10030306]

2.

Aviado DM, Porter JM. Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy. 1984 Nov-Dec;4(6):297-307. [PubMed: 6393073]

3.

Dawson DL, Cutler BS, Hiatt WR, Hobson RW, Martin JD, Bortey EB, Forbes WP, Strandness DE. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000 Nov;109(7):523-30. [PubMed: 11063952]

4.

Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ., American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):7S-47S. [PMC free article: PMC3278060] [PubMed: 22315257]

5.

Liang X, Wang Y, Zhao C, Cao Y. Systematic review the efficacy and safety of cilostazol, pentoxifylline, beraprost in the treatment of intermittent claudication: A network meta-analysis. PLoS One. 2022;17(11):e0275392. [PMC free article: PMC9624404] [PubMed: 36318524]

6.

Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017 Mar 21;135(12):e686-e725. [PMC free article: PMC5479414] [PubMed: 27840332]

7.

Jull AB, Arroll B, Parag V, Waters J. Pentoxifylline for treating venous leg ulcers. Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD001733. [PMC free article: PMC7061323] [PubMed: 23235582]

8.

Parker R, Armstrong MJ, Corbett C, Rowe IA, Houlihan DD. Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment Pharmacol Ther. 2013 May;37(9):845-54. [PubMed: 23489011]

9.

Patel V, Young H, Mellor A, Sproat C, Kwok J, Cape A, Mahendran K. The use of liquid formulation pentoxifylline and vitamin E in both established and as a prophylaxis for dental extractions "at risk" of osteoradionecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2023 Oct;136(4):404-409. [PubMed: 37316424]

10.

Paiva GLA, de Campos WG, Rocha AC, Júnior CAL, Migliorati CA, Dos Santos Silva AR. Can the prophylactic use of pentoxifylline and tocopherol before dental extractions prevent osteoradionecrosis? A systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2023 Jul;136(1):33-41. [PubMed: 36882364]

11.

Dissard A, P Dang N, Barthelemy I, Delbet C, Puechmaille M, Depeyre A, Pereira B, Martin F, Guillemin F, Biau J, Mirafzal S, Mom T, Gilain L, Saroul N. Efficacy of pentoxifylline-tocopherol-clodronate in mandibular osteoradionecrosis. Laryngoscope. 2020 Nov;130(11):E559-E566. [PubMed: 31747060]

12.

Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987 Jul;34(1):50-97. [PubMed: 3308412]

13.

Kamphuis J, Smits P, Thien T. Vascular effects of pentoxifylline in humans. J Cardiovasc Pharmacol. 1994 Oct;24(4):648-54. [PubMed: 7528848]

14.

Ciuffetti G, Mercuri M, Ott C, Lombardini R, Paltriccia R, Lupattelli G, Santambrogio L, Mannarino E. Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study. Eur J Clin Pharmacol. 1991;41(6):511-5. [PubMed: 1667754]

15.

Zhang M, Xu YJ, Mengi SA, Arneja AS, Dhalla NS. Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases. Exp Clin Cardiol. 2004 Summer;9(2):103-11. [PMC free article: PMC2716262] [PubMed: 19641695]

16.

Brasileiro JL, Inoye CM, Aydos RD, Silva IS, Falcão GR, Marks G, Pereira DM. Ischemia and reperfusion of rat small intestine using pentoxyfilline and prostaglandin E1. Acta Cir Bras. 2013 Nov;28(11):767-73. [PubMed: 24316743]

17.

Asvadi I, Hajipour B, Asvadi A, Asl NA, Roshangar L, Khodadadi A. Protective effect of pentoxyfilline in renal toxicity after methotrexate administration. Eur Rev Med Pharmacol Sci. 2011 Sep;15(9):1003-9. [PubMed: 22013722]

18.

Kwiecień S, Brzozowski T, Konturek PC, Pawlik MW, Pawlik WW, Kwiecień N, Konturek SJ. Gastroprotection by pentoxyfilline against stress-induced gastric damage. Role of lipid peroxidation, antioxidizing enzymes and proinflammatory cytokines. J Physiol Pharmacol. 2004 Jun;55(2):337-55. [PubMed: 15213357]

19.

Lin HI, Chu SJ, Wang D, Feng NH. Pharmacological modulation of TNF production in macrophages. J Microbiol Immunol Infect. 2004 Feb;37(1):8-15. [PubMed: 15060681]

20.

Vardareli E, Saricam T, Koken T, Degirmenci I, Aral E, Erenoglu E. The effect of alpha-tocopherol and pentoxyfilline on ischemia-reperfusion induced liver injury in rats. Hepatogastroenterology. 1998 Sep-Oct;45(23):1505-8. [PubMed: 9840094]

21.

Golbasi I, Akbas H, Ozdem S, Ukan S, Ozdem SS, Kabukçu H, Turkay C, Bayezid O. The effect of pentoxifylline on haemolysis during cardiopulmonary bypass in open-heart surgery. Acta Cardiol. 2006 Feb;61(1):7-11. [PubMed: 16485727]

22.

Mansourian S, Bina P, Fehri A, Karimi AA, Boroumand MA, Abbasi K. Preoperative oral pentoxifylline in case of coronary artery bypass grafting with left ventricular dysfunction (ejection fraction equal to/less than 30%). Anatol J Cardiol. 2015;15(12):1014-9. [PMC free article: PMC5368455] [PubMed: 25880052]

23.

Han SJ, Kim HJ, Kim DJ, Sheen SS, Chung CH, Ahn CW, Kim SH, Cho YW, Park SW, Kim SK, Kim CS, Kim KW, Lee KW. Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study. Diabetol Metab Syndr. 2015;7:64. [PMC free article: PMC4546105] [PubMed: 26300986]

24.

Vaizova OE, Vengerovsky AI, Alifirova VM. [Endothelium-protective effects of vinpocetine, pentoxifylline and enalapril in patients with chronic brain ischemia]. Eksp Klin Farmakol. 2011;74(4):10-3. [PubMed: 21678652]

25.

European Pentoxifylline Multi-Infarct Dementia Study. Eur Neurol. 1996;36(5):315-21. [PubMed: 8864715]

26.

Beermann B, Ings R, Månsby J, Chamberlain J, McDonald A. Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin Pharmacol Ther. 1985 Jan;37(1):25-8. [PubMed: 3965236]

27.

Poondru S, Devaraj R, Boinpally RR, Yamsani MR. Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects. Pharmacol Res. 2001 Mar;43(3):301-5. [PubMed: 11401423]

28.

Aviado DM, Dettelbach HR. Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication. Angiology. 1984 Jul;35(7):407-17. [PubMed: 6380349]

29.

De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol. 2009 Apr 07;15(13):1613-9. [PMC free article: PMC2669113] [PubMed: 19340904]

30.

Stana J, Stergar J, Gradišnik L, Flis V, Kargl R, Fröhlich E, Stana Kleinschek K, Mohan T, Maver U. Multilayered Polysaccharide Nanofilms for Controlled Delivery of Pentoxifylline and Possible Treatment of Chronic Venous Ulceration. Biomacromolecules. 2017 Sep 11;18(9):2732-2746. [PubMed: 28776978]

31.

Hosseini F, Mohammadbeigi A, Aghaali M, Borujerdi R, Parham M. Effect of pentoxifylline on diabetic distal polyneuropathy in type 2 diabetic patients: A randomized trial. J Res Med Sci. 2019;24:89. [PMC free article: PMC6856542] [PubMed: 31741661]

32.

Furukawa S, Matsubara T, Umezawa Y, Motohashi T, Ino T, Yabuta K. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease. Eur J Pediatr. 1994 Sep;153(9):663-7. [PubMed: 7957426]

33.

Best BM, Burns JC, DeVincenzo J, Phelps SJ, Blumer JL, Wilson JT, Capparelli EV, Connor JD., Pediatric Pharmacology Research Unit Network. Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. Curr Ther Res Clin Exp. 2003 Feb;64(2):96-115. [PMC free article: PMC4053025] [PubMed: 24944359]

34.

Yasui K, Ohta K, Kobayashi M, Aizawa T, Komiyama A. Successful treatment of Behçet disease with pentoxifylline. Ann Intern Med. 1996 May 15;124(10):891-3. [PubMed: 8610918]

35.

Sacerdote A. Treatment of homozygous sickle cell disease with pentoxifylline. J Natl Med Assoc. 1999 Aug;91(8):466-70. [PMC free article: PMC2608440] [PubMed: 12656436]

36.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Jul 20, 2020. Pentoxifylline. [PubMed: 30000441]

37.

Plotnikov MB, Shamanaev AY, Aliev OI, Sidekhmenova AV, Anishchenko AM, Arkhipov AM. Pentoxifylline treatment enhances antihypertensive activity of captopril through hemorheological improvement in spontaneously hypertensive rats during development of arterial hypertension. J Am Soc Hypertens. 2017 Nov;11(11):769-778. [PubMed: 28989072]

38.

Namdar H, Khani E, Pourrashid MH, Entezari-Maleki T. Effects of Adding Pentoxifylline to Captopril on Primary Hypertension: A Pilot Randomized Clinical Trial. J Clin Pharmacol. 2020 Feb;60(2):181-187. [PubMed: 31489650]

39.

Garcia FA, Pinto SF, Cavalcante AF, Lucetti LT, Menezes SM, Felipe CF, Alves AP, Brito GA, Cerqueira GS, Viana GS. Pentoxifylline decreases glycemia levels and TNF-alpha, iNOS and COX-2 expressions in diabetic rat pancreas. Springerplus. 2014;3:283. [PMC free article: PMC4070224] [PubMed: 24991532]

40.

Fang JH, Chen YC, Ho CH, Chen JY, Hsing CH, Liang FW, Wu CC. The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment. Sci Rep. 2021 Jun 29;11(1):13521. [PMC free article: PMC8241975] [PubMed: 34188087]

41.

Barnes PJ. Theophylline. Am J Respir Crit Care Med. 2013 Oct 15;188(8):901-6. [PubMed: 23672674]

42.

Leehey DJ, Carlson K, Reda DJ, Craig I, Clise C, Conner TA, Agarwal R, Kaufman JS, Anderson RJ, Lammie D, Huminik J, Polzin L, McBurney C, Huang GD, Emanuele NV. Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial. BMJ Open. 2021 Aug 16;11(8):e053019. [PMC free article: PMC8370537] [PubMed: 34400461]

43.

Chen L, Gao Y, Liu M, Li Q, Han C, Zhao Y, Li B, Xu J, Dai Y, Li P, Li J, Li Y, Ran X. Efficacy and safety of pentoxifylline for chronic venous leg ulcers: study protocol for a multicenter randomized controlled trial in China (ESPECT study). Trials. 2023 Aug 02;24(1):491. [PMC free article: PMC10394857] [PubMed: 37533132]

44.

Carballada F, Guitián L, Nuñez R, Lopez R, Pineda F, Boquete M. Anaphylaxis due to pentoxifylline. J Investig Allergol Clin Immunol. 2014;24(6):457-8. [PubMed: 25668904]

45.

Salhiyyah K, Forster R, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 2015 Sep 29;9(9):CD005262. [PMC free article: PMC6513423] [PubMed: 26417854]

46.

Silver MR, Kroboth PD. Pentoxifylline in end-stage renal disease. Drug Intell Clin Pharm. 1987 Dec;21(12):976-8. [PubMed: 3428162]

47.

Eden G, Busch M, Kühn-Velten WN, Schneider A, Kielstein JT. Successful treatment of life-threatening pentoxifylline intoxication by high-flux hemodialysis. Clin Nephrol. 2011 Feb;75(2):171-3. [PubMed: 21255548]

48.

Sein Anand J, Wiergowski M, Wiśniewski MR, Kosmowska M, Kata M, Woźniak MK. Fatal Suicidal Intoxication with Pentoxifylline Complicated by Cardiovascular Disorders. Toxics. 2022 Aug 03;10(8) [PMC free article: PMC9414985] [PubMed: 36006127]

49.

Brook-Barclay L, Delaney CL, Scicchitano M, Quinn S, Spark JI. Pharmacist influence on prescribing in peripheral arterial disease (PIPER). Vasc Med. 2014 Apr;19(2):118-124. [PubMed: 24557808]

Disclosure: Pavan Annamaraju declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Krishna Baradhi declares no relevant financial relationships with ineligible companies.